Pharmapedia

Eli Lilly has provided new insights into retatrutide, its investigational medicine that is attracting significant attention for its potential to treat obesity, type 2 diabetes, and several obesity-related health conditions. While the therapy remains under clinical development and is not yet approved for public use, ongoing research suggests it could become one of the most impactful treatments in the rapidly growing obesity care market.

Chronic pancreatitis (CP) is often recognized for the severe abdominal pain it causes, but new research from Mayo Clinic suggests that the disease affects far more than pain alone. The study reveals that CP significantly impacts mobility, self-care, routine activities, mental well-being, and overall quality of life, highlighting the need for a more comprehensive approach to patient care.
The findings were first made available online on August 27, 2025, and later published in the Journal of Pancreatology (Volume 9, Issue 1) on March 30, 2026.

Artificial intelligence is rapidly moving into one of medicine’s most critical areas — cardiac arrest care, with researchers reporting that AI tools may soon help doctors predict cardiac arrests, guide CPR decisions, improve emergency response systems, and support recovery planning after resuscitation.

A new review published in the World Journal of Emergency Medicine examined how artificial intelligence is being applied across the full chain of cardiac arrest care, from early risk detection to post-resuscitation recovery.

A newly introduced drug approval pathway in the United Kingdom is facing criticism from healthcare experts, who argue that the system may favor pharmaceutical companies more than patients or the public healthcare system. According to an analysis published in The BMJ, the accelerated process could lead to quicker market access for medicines without guaranteeing meaningful benefits for patients.

In a landmark medical breakthrough, the U.S. Food and Drug Administration has approved the world’s first gene therapy designed to treat a rare form of inherited hearing loss, marking a major step toward curing, not just managing, deafness.

India has moved a decisive step closer to having its first tetravalent dengue vaccine on the market after a Subject Expert Committee (SEC) under the Drugs Controller General of India (DCGI) recommended approving Takeda Biopharmaceuticals' Dengue Tetravalent Vaccine (TDV) for import and use in individuals aged 4 to 60 years.

Mounjaro (tirzepatide) has emerged as one of the most impactful brands in the GLP‑1 category, showing remarkable traction over the last nine months. With growing acceptance among clinicians and increasing awareness among patients, Mounjaro’s performance reflects both strong clinical confidence and rising demand in the metabolic therapy space.

Vinay Kumar Singh. 
Head-Formulation
Kumar Organic Products Research Centre Pvt. Ltd.,
Bengaluru
Email : formulation_krc@kopresearchcentre.net